Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity.

Santini S, Vionnet N, Pasquier J, Gonzalez-Rodriguez E, Fraga M, Pitteloud N, Favre L

Obesity (Silver Spring, Md.)7 Dec 2022Cited by 29 (Europe PMC)

PMID36478514PMCIDPMC10107497DOI10.1002/oby.23596PepBankPUB-36478514

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity, percentage weight loss on liraglutide 3.0 mg averaged 12.4% (14.1 kg) at 10 months.
In plain wordsIn adults with obesity in a real-life setting, liraglutide 3.0 mg was followed by an average weight loss of 12.4% at 10 months.
Peptide
Liraglutide
Outcome
DecreasePercentage weight loss at 10 months
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Measurements
Weight loss
−12.4%
10 months
Weight loss
−14.1 kg
10 months
Source sentences
Summary
At 10 months, mean (SD) percentage weight loss (WL%) was -12.4% (5.5%) or -14.1 (6.6) kg.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851401
02HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, 87% of patients had weight loss of at least 5% at 4 months.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, 87% had lost at least 5% of their weight by 4 months.
Peptide
Liraglutide
Outcome
DecreasePatients with weight loss of at least 5% at 4 months
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 4 monthsAs given in this study (human).
Measurements
Responders WL >=5%
87%
4 months
Source sentences
Summary
WL% was ≥5% in 87% of patients at 4 months
1 context sentence(design, population, supporting numbers)
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851402
03HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, 96% of patients had weight loss of at least 5% at 10 months.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, 96% had lost at least 5% of their weight by 10 months.
Peptide
Liraglutide
Outcome
DecreasePatients with weight loss of at least 5% at 10 months
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Measurements
Responders WL >=5%
96%
10 months
Source sentences
Summary
WL% was ≥5% in 87% of patients at 4 months and in 96% at 10 months.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851403
04HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, percentage weight loss was higher in women than in men at 4 months and persisted at 10 months.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, women lost a larger percentage of their weight than men.
Peptide
Liraglutide
Outcome
Not applicableWeight loss by sex
Study
n = 54
Comparator
Men
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Measurements
WL% women
−13.7%
10 months
WL% men
−9.6%
10 months
Source sentences
Summary
WL% was higher in women (-9.5% [3.1%] vs. men -7.2% [2.5%], p = 0.02) at 4 months and persisted at 10 months (-13.7% [5.2%] vs. -9.6% [5.1%], p = 0.006).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851404
05HumanObservational studyOther
In adults with obesity on liraglutide 3.0 mg, percentage weight loss was associated with baseline percentage fat mass but not with age or BMI.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, weight loss was linked to starting body fat percentage, not to age or BMI.
Peptide
Liraglutide
Outcome
Not applicableAssociation of weight loss with baseline fat mass, age and BMI
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Source sentences
Summary
WL% was associated with baseline percentage fat mass but not with age or BMI.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851405
06HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, DXA-measured fat mass decreased.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, body fat mass decreased.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Source sentences
Summary
Body composition showed a decrease in fat mass, visceral adipose tissue, and absolute lean mass.
2 context sentences(design, population, supporting numbers)
Summary · context
Body composition was assessed by dual-energy x-ray absorptiometry at baseline and 10 months.
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851406
07HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, visceral adipose tissue decreased.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, fat around the organs decreased.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Source sentences
Summary
Body composition showed a decrease in fat mass, visceral adipose tissue, and absolute lean mass.
2 context sentences(design, population, supporting numbers)
Summary · context
Body composition was assessed by dual-energy x-ray absorptiometry at baseline and 10 months.
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851407
08HumanObservational studyEfficacy outcome
In adults with obesity on liraglutide 3.0 mg, absolute lean mass decreased.
In plain wordsIn adults with obesity on liraglutide 3.0 mg, lean (non-fat) body mass also decreased.
Peptide
Liraglutide
Outcome
DecreaseAbsolute lean mass
Study
n = 54
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · 10 monthsAs given in this study (human).
Source sentences
Summary
Body composition showed a decrease in fat mass, visceral adipose tissue, and absolute lean mass.
2 context sentences(design, population, supporting numbers)
Summary · context
Body composition was assessed by dual-energy x-ray absorptiometry at baseline and 10 months.
Summary · context
Adult patients with BMI > 35 kg/m² , or BMI > 28 kg/m² with greater than or equal to one metabolic comorbidity, were included (n = 54, 65% women).
Report a problemFND-3647851408

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.